DSG3 and myasthenia gravis: CAAR T cell therapy is particularly relevant for diseases driven by well-defined autoantigens, such as muscle-specific tyrosine kinase (MuSK) in myasthenia gravis or desmoglein 3 (DSG3) in pemphigus vulgaris (86, 87).